PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30224540-1	2019	The sodium iodide symporter (SLC5A5/NIS) as theranostic gene would allow for non-invasive imaging of functional NIS expression and therapeutic radioiodine application.	Iodine-131	143-154	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	4-27	
32292510-2	2020	NIS is a theranostic protein that allows non-invasive monitoring of the in vivo biodistribution of functional NIS expression by radioiodine imaging as well as the therapeutic application of 131I.	Iodine-131	128-139	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	0-3	
32292510-2	2020	NIS is a theranostic protein that allows non-invasive monitoring of the in vivo biodistribution of functional NIS expression by radioiodine imaging as well as the therapeutic application of 131I.	Iodine-131	128-139	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	110-113	
31010838-1	2019	PURPOSE: New strategies to restore sodium iodide symporter (NIS) expression and function in radioiodine therapy-refractive anaplastic thyroid cancers (ATCs) are urgently required.	Iodine-131	92-103	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	60-63	
30224540-1	2019	The sodium iodide symporter (SLC5A5/NIS) as theranostic gene would allow for non-invasive imaging of functional NIS expression and therapeutic radioiodine application.	Iodine-131	143-154	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	29-35	
30224540-10	2019	IMPLICATIONS: These data expand the prospect of MSC-mediated radioiodine imaging-guided therapy of pancreatic cancer using the sodium iodide symporter as a theranostic gene in a clinical setting.	Iodine-131	61-72	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	127-150	
28380420-7	2017	Administration of 131I in LPEI-PEG-GE11/NIS-treated mice resulted in significantly reduced tumor growth compared to controls as determined by magnetic resonance imaging, though survival was not significantly prolonged.	Iodine-131	18-22	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	40-43	
27458162-0	2016	Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery.	Iodine-131	17-21	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	101-124	
21851208-0	2011	Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.	Iodine-131	29-40	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	105-128	
21204761-0	2010	Human sodium iodide symporter added to multidrug resistance 1 small hairpin RNA in a single gene construct enhances the therapeutic effects of radioiodine in a nude mouse model of multidrug resistant colon cancer.	Iodine-131	143-154	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	6-29	
21575476-0	2011	[Transfer of sodium iodide symporter gene into glioma cells by recombinant adenovirus and radioiodine therapy for the glioma cells in vitro and in nude mice].	Iodine-131	90-101	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	13-36	
19789324-0	2009	Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.	Iodine-131	9-20	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	97-120	
19789324-1	2009	PURPOSE: We recently reported the significant therapeutic efficacy of radioiodine therapy in various tumor mouse models following transcriptionally targeted sodium iodide symporter (NIS) gene transfer.	Iodine-131	70-81	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	157-180	
17611400-0	2007	In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter.	Iodine-131	30-41	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	53-76	
15735035-6	2005	Radioiodination via an indirect method attenuated uptake of radioiodine in tissues that express the Na/I symporter without affecting the ability to image the tumor xenografts.	Iodine-131	60-71	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	100-114	
11704812-1	2001	Radioiodine therapy, the most effective form of systemic radiotherapy available, is currently useful only for thyroid cancer because of thyroid-specific expression of the sodium iodide symporter (NIS).	Iodine-131	0-11	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	171-194